year left
short interest float
pharma epix preclin stage pharmaceut compani focus
develop novel therapi address prostat cancer compani first-
gener candid ralaniten acet n-termin domain inhibitor ntd
androgen receptor ar one driver advanc prostat cancer preclin
data phase studi provid insight potenti ntd inhibit
point need second-gener ntd inhibit compound higher potenc
bioavail current complet preclin studi second-gener
compound expect design lead compound first half follow
ind file first quarter novel compound potenti
salvag option advanc prostat cancer patient either refractori
resist approv antiandrogen therapi well up-front treatment option
combin drug knowledg ntd inhibitor ar
develop treatment strategi potenti address larg unmet medic
point discuss
epi aniten develop target n-termin domain ar
prostat cancer epi aniten compound relat structur deriv bisphenol
diglycid ester badg origin isol marin spong pacif ocean
grant uniqu usan drug stem aniten meant design n-
termin domain inhibitor ntd androgen receptor ar compound bind
ntd ar requir ar transcript activ preclin studi
activ singl isom aniten compound inhibit cell prolifer limit
tumor growth model prostat cancer compani first-gener
aniten compound show sign activ favor safeti profil howev
studi conclud need potent compound greater bioavail use
knowledg gain clinic studi taken seri step
improv upon drug next-gener aniten compound knowledg
essa aniten compound therapi develop target ntd
repres novel treatment approach patient castrat resist prostat cancer
 design lead aniten compound ind-en studi
 advanc discuss strateg partner regard collabor
 file ind lead aniten compound mcrpc
analyst certif disclosur pleas see page
aniten compound could complement emerg clinic applic prostat cancer
treatment landscap prostat cancer rapidli evolv evidenc recent data suggest
combin johnson johnson nyse zytiga abirateron -a second gener antiandrogen-
androgen deprav therapi explor potenti up-front treatment option advanc
prostat cancer therefor expand patient popul avail antiandrogen therapi essa
shown enhanc activ astella tyo nyse xtandi enzalutamid
anti-ar therapi vitro model highlight possibl therapeut approach
import consid second-gener antiandrogen becom part up-front treatment regimen
therapi need combat eventu resist enhanc ar inhibit
aniten may offer salvag option pc patient fail antiandrogen therapi although
antiandrogen therapi enzalutamid abirateron shown efficaci treatment advanc
prostat cancer men respond either therapi moreov patient respond
treatment ultim relaps popul repres substanti market opportun
retrospect analysi liquid biopsi patient show ar splice variant ar-v present
half individu treat abirateron enzalutamid nearli resist
either treatment note therapi advanc stage develop target ar may
prone eventu resist target ntd aniten compound would inhibit region
ar associ resist could address patient progress diseas
knowledg gain phase prostat cancer studi inform path forward compani
complet phase studi show favor safeti profil modest activ men
mcrpc demonstr reduct prostat specif antigen howev studi highlight
limit relat potenc bioavail formul stabil led take
seri step improv upon next gener aniten compound includ screen
compound higher potenc favor absorpt distribut metabol excret adm
prolif compani identifi number potenti candid plan design lead aniten
compound ind-en studi first half follow ind file mcrpc
first quarter
capit follow januari follow-on offer experienc manag
januari recent complet million capit rais help fund preclin
ind phase studi addit compani also partial fund cancer prevent research
institut texa ciprit grant repres sourc non-dilut capit manag team
year experi biopharmaceut space drug develop
year end financi year end septemb pharma report net loss million
per share compar net loss million per share period
research develop expens million compar million year end septemb
gener administr cost million compar million period
septemb report million cash hand
new list tsx ventur exchang novemb announc list
common share tsx ventur exchang tsxv symbol epi time compani
appli voluntari delist toronto stock exchang tsx
recent equiti offer recent close equiti offer aggreg gross proce million
compani issu common share pre-fund common share warrant
aggreg gross proce respect privat placement issu common
share certain director compani aggreg proce
januari announc close addit broker equiti offer million well
partial exercis over-allot option addit proce roughli million compani issu
common share pre-fund common share warrant whole
rais total gross proce approxim million
tabl content
mechan action
target ar pathway prostat cancer
mechan resist ar target therapi
caus molecular basi prostat cancer
symptom diagnosi stage
phase i/ii trial metastat castrat resist prostat cancer
plan phase trial next-gener aniten compound
drug develop
risk invest
pharma pharmaceut compani focus develop novel therapi prostat cancer
compani first-gener drug candid ralaniten acet part famili n-termin inhibitor
androgen receptor ar grant uniqu usan drug stem aniten meant design
n-termin domain ntd inhibitor ar therapi distinguish antiandrogen therapi
target ntd ar target ntd epi aniten compound potenti target ar splice
variant ar ligand bind domain lbd mutat implic resist current therapi
repres area larg unmet medic need
figur show compani develop pipelin recent complet phase dose-escal portion
phase i/ii studi men metastat castrat resist prostat cancer mcrpc progress
enzalutamid treatment result show favor safeti profil modest
reduct higher dose cohort howev studi identifi limit relat
bioavail formul stabil septemb refocus activ toward identifi new
aniten compound higher potenc improv absorpt distribut metabol excret adm
prolif compani complet preclin studi new aniten compound expect file ind
compound first quarter
first-in-class inhibitor termin domain ntd androgen receptor ar compound
relat structur deriv bisphenol diglycid ester badg origin isol
marin spong geodia lindgreni target ntd ar present potenti therapeut option men
newli diagnos estim new case prostat cancer diagnos us
year larg unmet need due inevit resist exist therapi section provid
background ar signal mechan resist ar target therapi lastli describ proof concept
preclin data support develop aniten compound
mechan action ralaniten acet prodrug relat origin identifi
marin spong extract activ singl isom structur compound depict
left panel figur isom bind portion n-termin ntd domain
androgen receptor ar shown right panel figur bound domain ar drug
inhibit protein-protein interact creb-bind protein larg subunit transcript factor
tfiif requir ar transcript activ ar ligand-depend transcript factor activ
androgen involv regul reproduct process bodi hyper-activ
signal pathway shown one driver mcrpc
figur structur mechan action
next-gener aniten n-termin domain inhibitor perform structur activ relationship
sar studi identifi next gener ntd inhibitor aniten compound compani decid
refocu effort phase studi uncov limit relat potenc bioavail stabil
compani focus develop next gener ntd inhibitor preserv
mechan action significantli improv potenc pharmacolog properti drug accord
initi screen data indic second-gener compound potent
improv absorpt distribut metabol excret adm prolif compar
androgen steroid hormon involv variou development process includ male sexual
differenti mainten spermatogenesi male gonadotropin regul gonadotropin releas hormon
gnrh involv releas follicle-stimul hormon fsh lutein hormon lh
anterior pituitari fsh lh act synergist regul reproduct process bodi androgen
exert effect androgen receptor ar ligand-depend transcript factor multipl
function domain depict figur domain ntd receptor contain
transactiv domain mediat ar transcript activ ntd follow dna-
bind domain made two zinc-fing bind motif preferenti bind invert
repeat androgen respons element ggtacnnntgttct remaind protein transcript activ
carri ligand bind domain lbd contain ligand-bind pocket absenc
androgen ar kept nucleu due interact heat shock protein ar bound
androgen ar undergo conform chang induc entri nucleu upon enter
nucleu ar interact androgen respons element recruit transcript co-regul start
transcript target
normal physiolog condit ar signal maintain proper architectur function prostat
howev upregul ar signal axi lead deregul ar target gene promot
uncontrol cellular prolifer cell surviv uncontrol prolifer set androgen
depend sinc withdraw either castrat pharmacolog mean limit prolifer reduc tumor
target ar pathway prostat cancer fact limit androgen result lower tumor burden led
develop therapeut regimen decreas system androgen histor done either
orchiectomi surgic remov testicl medic castrat lutein hormon releas therapi
refer androgen deprav therapi method control diseas sever year
case cur howev long-term often result resist subsequ progress diseas
lead state refer either castrat resist prostat cancer hormon refractori prostat
cancer prostat cell continu prolifer even presenc low level testosteron
case patient still aid form hormon therapi block androgen activ name
johnson johnson zytiga abirateron astellas/pf xtandi enzalutamid
mechan resist ar target therapi mediat either ar-depend ar-
independ mechan shown figur signal ar crucial surviv cell
mediat variou mechan includ overexpress amplif ar synthesi androgen
anantharaman et al target androgen receptor metastat castrate-resist prostat cancer review
harri et al androgen depriv therapi progress understand mechan resist optim
imamura et al androgen receptor target therapi castration-resist prostat cancer bench clinic
within cell mutat ar develop aberr ar splice studi evalu ar-
independ resist recent identifi increas activ fgfr mapk signal pathway
possibl mechan follow section briefli describ ar-depend mechan
resist essa epi aniten compound specif design circumv
figur mechan resist ar therapi
compani present lifesci capit
approxim patient consid resist therapi amplif ar gene
elev level ar mrna interestingli primari tumor patient amplif
ar locu rais possibl castrat therapi may play role evolut tumor toward
increas ar thought help increas sensit androgen low level due one
possibl explan mechan resist expans cell ar locu amplifi
normal condit primari tumor cell respond therapi howev evid
prostat cell amplifi ar select base abil thrive low androgen
environ altern hypothesi suggest amplif ar product tumor cell evolv
time way cope androgen depriv
tumor cell also increas sensit androgen produc local achiev increas
express enzym involv activ dihydrotestosteron activ
metabolit testosteron consid potent agonist androgen receptor increas
level activ tumor cell would otherwis respond abl surviv addit
format intratumor cell also gener androgen cholesterol dehydroepiandrosteron
chandrasek et al mechan resist castration-resist prostat cancer tran andr urol
bluemn et al androgen receptor pathway-independ prostat cancer sustain fgf signal cancer
robinson et al integr clinic genom advanc prostat cancer cell
antonaraki et al androgen receptor variant-driven prostat cancer clinic implic therapeut target
mutat within ar shown confer surviv advantag cancer cell well document
mechan exampl acquisit mutat within ligand bind domain lbd ar
shown result activ relat androgen dehydroepiandrosteron progesteron
glucocorticoid outsid mutat studi also identifi alter within ar
convert ar antagonist therapi agonist well mutat confer resist current crpc
therapi mutat within function domain ar also shown alter gene express instanc
genet alter n-termin domain ntd dna bind domain ar also increas ar
signal alter bind corepressor induc transcript activ target gene final mutat
within ar alter result constitut activ receptor truncat form
ar lack c-termin domain shown enhanc metastat potenti
one way cell regul function gene product altern splice gener
process allow one gene code multipl protein order happen exon within gene either
includ exclud gener protein variou function approxim differ ar splice
variant document prostat cancer thu far sever ar splice variant identifi clinic tumor sampl
lack lbd receptor suggest could constitut activ function independ androgen
variou studi identifi ar splice variant
clinic signific particular ar- shown upregul compar
hormon nave prostat cancer consist local nucleu constitut activ
splice variant may function conjunct full length ar ar-fl regul ar-fl
clinic studi evalu express circul tumor cell patient receiv hormon
therapi found deem posit less respons therapi evidenc prostate-
specif antigen respons posit patient compar neg patient
protein produc cell prostat use measur diseas burden median clinic progress
free surviv posit men treat hormon therapi month compar month
neg patient interestingli transcript also express normal human tissu
includ spleen placenta lung brain howev function role human tissu remain
find may confer resist hormon therapi led develop novel
therapeut essa epi aniten compound target ar ntd
pharma conduct seri vitro vivo experi support develop
epi aniten compound vivo experi epi n-termin domain ntd inhibitor
compound aniten demonstr activ murin model castrat resist prostat cancer
vitro experi cell line shown epi compound limit cell prolifer specif inhibit
androgen receptor ar activ addit compani shown enhanc efficaci activ form
lock et al androgen level increas intratumor de novo steroidogenesi progress castration-
lu et al decod androgen receptor slice variant transl androl urol
lu et al androgen receptor variant substitut full-length receptor urol
antonaraki et al resist enzalutamid abirateron prostat cancer new engl
combin approv antiandrogen therapi result highlight potenti epi aniten
compound singl agent combin antiandrogen treatment limit cell prolifer metastat
activ preclin model prodrug use
phase i/ii studi patient mcrpc fail either abirateron enzalutamid
therapi preclin model mcrpc decreas prolifer slow tumor growth compar
enzalutamid data studi depict figur cell larg depend
express cultur presenc vehicl control enzalutamid treat cell
subsequ incub presenc bromodeoxyuridin brdu order measur prolifer time
brdu significantli lower cell treat compar vehicl enzalutamid
treat cell left panel order examin potenti vivo anti-canc effect
immunocompromis mice receiv xenograft cell treat vehicl
enzalutamid tumor volum reach approxim mice castrat
subsequ treat vehicl twice-daili mg/kg once-daili mg/kg enzalutamid tumor
mice treat either enzalutamid red line blue grew slower rate compar vehicl
black treat mice note limit tumor growth greater degre enzalutamid treatment
suggest greater efficaci particular model
figur brdu incorpor tumor growth respons
compani present yang et al
bind ar limit prolifer analog epi use imag full length
androgen receptor fl-ar ar splice variant ar-v accord compound mimic
chemic properti second gener aniten compound evalu in-hous vitro
experi use show compound abl bind ar limit prolifer target fl-ar
ar-v vivo data studi shown figur treat either
yang et al target androgen receptor epi overcom resist mechan castration-
imamura et al imag agent detect androgen receptor activ splice variant prostat cancer
presenc vehicl control cell lysat treat cell subsequ probe fl-ar express
repres two band around kilo-dalton kda left panel detect radio-label
examin use phosphorimag panel show evid around kda lane
coincid band fl-ar addit non-radiolabel seem displac given
lack band around kda lane suggest compet ar order evalu
effect cell prolifer cell evalu abil incorpor brdu panel
show dose depend decreas brdu incorpor respons treatment suggest
abl reduc prolifer cell dose depend manner
final experi perform examin vivo target abil
immunocompromis mice receiv cell xenograft left flank cell right flank
mice treat imag use whole-bodi micro-single-photon emiss computer
tomography/comput tomographi spect/ct color scale indic intens
greater cell compar xenograft panel unblock note highli
local liver may make sens given administ tail vein inject
liver main organ drug metabol contrast tracer elimin
cell mice treat non-radiolabel panel block highlight abil target
figur bind ar activ cell
greater ar inhibit combin ar lbd inhibitor evalu abil
enhanc inhibit ar activ test alon combin enzalutamid vitro
model measur transcript activ cell transfect probasin-luciferas
report plasmid read luciferas consequ endogen ar activ lncap fl-ar green bar
shown figur separ treatment either enzalutamid result approxim
inhibit luciferas activ normal untreat cell contrast combin treatment plu
enzalutamid enhanc inhibit ar activ compar either treatment
order determin consequ treatment cell express fl-ar lncap
cell co-transfect probasin-luciferas report plasmid express vector induc high
express transfect cell separ treat enzalutamid
combin drug analyz luciferas activ grey bar figur depict result epi-
inhibit ar transcript activ greater degre enzalutamid treatment note
combin enzalutamid enhanc inhibit probasin-luciferas report
support potenti clinic evalu combin advanc prostat cancer
figur transcript activ ar cell treat enzalutamid
complet phase portion dose escal expans phase i/ii studi evalu men
metastat experienc progress treatment abirateron enzalutamid patient
fail one regimen docetaxel chemotherapi also includ subject report moder
common diarrhea fatigu decreas appetit patient
highest dose cohort mg report gastrointestin event lead studi discontinu dose-limit
toxic dlt anoth patient mg report transient elev aspart transaminas ast
alanin transaminas alt led discontinu enrol mg dose cohort patient
twice day mg cohort continu treatment addit safeti concern overal safeti
toler data support develop compound similar profil
prostat gland male reproduct system locat pelvi urinari bladder prostat
contain gland produc compon semin fluid develop mainten structur integr
prostat control androgen testosteron signal cognat receptor
androgen receptor ar prostat cancer aris cell within prostat begin prolifer uncontrol
cancer develop variou histolog form includ adenocarcinoma common form prostat
cancer sarcoma small cell carcinoma neuroendocrin tumor translat cell carcinoma although exact
caus malign unknown variou risk factor genet alter associ diseas
prostat cancer associ androgen mani compani target ar led
clinic success term limit tumor growth howev therapi target ar ligand bind domain
invari induc resist variou mechan describ current develop epi aniten
compound design target n-termin domain ar way treat refractori diseas
caus molecular basi prostat cancer
caus prostat cancer unknown primari risk factor age ethnic presenc rel
diseas associ found prostat cancer high blood pressur lack exercis
genet background clearli play import role alter genet background either turn cancer
caus gene turn cancer protect gene genet chang inherit often
link gene dna repair pathway includ comprehens profil
prostat cancer tumor identifi fusion androgen-regul erg gene oncogen member
erythroblast transformation-specif relat transcript factor famili common alter
prostat cancer commonli mutat gene includ spop enhanc ar-driven
transcript human prostat factor may increas risk develop prostat cancer
obes smoke inflamm prostat
symptom diagnosi stage
symptom men earli stage prostat cancer usual symptom cancer progress patient
experi weak interrupt urin flow frequent urin blood urin pain burn sensat
urin men advanc diseas often develop bone metastasi frequent experi pain hip spine
rib well area
screen prostat specif antigen compon semin fluid produc almost exclus
prostat shown elev men prostat cancer screen minim invas
blood test measur serum level first line defens screen malign
use screen method recent call recommend intend
avoid unnecessari potenti harm procedur inevit result prostat cancer miss
anoth diagnost techniqu proven effect primari prostat cancer screen like
remain major diagnost determin prostat cancer earli fda approv progensa
assay first molecular test help determin need repeat prostat biopsi men
tcga molecular taxonomi primari prostat cancer cell
previou neg biopsi new diagnost like test expect play critic role diagnos prostat
cancer futur
test usual accompani digit rectal examin physician use ascertain
size shape textur prostat either test posit patient may refer undergo
prostat imag might includ ultrasound magnet reson imag mri procedur may
help diagnosi definit way definit diagnos prostat cancer prostat biopsi
howev american urolog associ aua specifi serum level singl factor
would trigger biopsi associ recommend primari factor decid
recommend biopsi age famili histori prior biopsi histori comorbid
biopsi urologist obtain approxim sampl lobe prostat sampl total
use core needl out-pati procedur biopsi sampl examin microscop
pathologist determin presenc cancer sever cancer determin given score accord
gleason grade system
gleason score gleason grade system one primari diagnost tool use help evalu
prognosi men prostat cancer gleason score determin base pathologist qualit
determin charact cell examin use scale pathologist grade common
tumor pattern second-most common tumor pattern observ biopsi cell number two
pattern ad togeth determin gleason score gleason score indic best prognosi
worst figur show graphic depict pathologist look order determin
gleason score
figur graphic represent gleason scale
nation institut nih
gleason scale evolv applic sinc first use order standard gleason
system intern societi urolog patholog publish consensu guidelin gleason
grade system describ follow acini cluster cell resembl raspberri depict
figur
pattern circumscrib nodul close pack separ uniform round oval medium-s
pattern like pattern fairli circumscrib yet edg tumor nodul may minim
infiltr gland loos arrang quit uniform gleason pattern
pattern discret glandular unit typic smaller gland seen gleason pattern infiltr
amongst non-neoplast prostat acini mark variat size shape smoothli circumscrib
small cribriform nodul tumor
pattern fuse microacinar gland ill-defin gland poorli form glandular lumina larg
cribriform gland cribriform gland irregular border hypernephromatoid
pattern essenti glandular differenti compos solid sheet cord singl cell
comedocarcinoma central necrosi surround papillari cribriform solid mass
prostat cancer stage patient cancer stage base result biopsi use determin
gleason score well combin factor includ level metastasi
evalu lymph node imag depict figur repres differ stage prostat cancer
describ detail
epstein et al intern societi urolog patholog isup consensu confer gleason
grade prostat carcinoma american journal surgic patholog
figur stage prostat cancer
differ stage prostat cancer describ follow addit qualit descript given serum
gleason criteria may also associ stage
stage cancer confin prostat microscop detect
imag techniqu cancer detect biopsi surgeri anoth reason gleason score
indic cancer tissu resembl normal tissu
stage iia tumor still confin prostat gland larger stage cancer stage ii
cancer detect imag tumor confin one lobe prostat
gleason score
stage iib criteria stage iia howev tumor found lobe prostat
stage tumor spread beyond outer layer prostat tumor may begun spread
nearbi tissu semin vesicl tumor gleason score
stage iv stage iv prostat cancer tumor spread beyond prostat semin vesicl
metastas part bodi commonli lymph node bone rectum bladder liver
lung tumor gleason score
treatment option men diagnos prostat cancer larg depend sever malign fall
well-defin treatment paradigm decis treatment made base combin factor includ
gleason score famili histori sequenc therapi base variou patholog indic
patient diseas determin slow-grow immedi treatment need
patient close monitor sign diseas progress otherwis receiv treatment treatment
cours refer activ surveil often chosen older patient patient may never
receiv treatment die caus younger men activ surveil often mean put treatment
order avoid side effect
treatment prostat cancer undesir side effect often includ sexual dysfunct urinari
incontin lead mani patient doctor choos activ surveil diseas progress
patient aggress form cancer high risk due famili histori treatment initi
immedi patient diagnos local diseas surgeri radiat offer therapeut option
cur potenti androgen deprav therapi nyse lupron leuprolid
acet astrazeneca nyse azn zoladex goserelin often use patient relaps continu use
recommend prostat cancer sensit hormon therapi
although may effect limit diseas tumor invari becom refractori patient relaps
state refer castrat resist prostat cancer first-lin standard care patient
hormon treatment flutamid bicalutamid docetaxel chemotherapi follow
cabazitaxel antiandrogen therapi johnson johnson nyse zytiga abirateron
astellas/pf tyo /nyse xtandi enzalutamid although therapi repres signific
advanc treatment prostat cancer larg segment patient either refractori
antiandrogen therapi becom resist initi respons therapi therefor
repres area larg unmet medic need essa aniten compound could use address problem sinc
therapi may effect mani document mechan resist antiandrogen treatment
note valeant nyse vrx proveng sipuleucel-t label asymptomat non-metastat patient
bayer bayn xofigo alpharadin chlorid often use treatment patient bone
metastasi list approv treatment shown figur
prostat cancer treatment landscap move toward combin approach standard
chemotherapi antiandrogen therapi newli diagnos metastat prostat cancer combinatori strategi
support compel data show increas surviv benefit either combin therapi
sweeney et al long term efficaci qol data chemohormon therapi c-ht low high volum
hormon nave metastat prostat cancer praca chaart trail annal oncolog
jame et al addit docetaxel zoledron acid first-lin long-term hormon therapi prostat
cancer stamped surviv result adapt muliarm multistag platform randomis control trial lancet
fizazi et al abirateron plu prednison metastat castrat sensit prostat cancer new engl jour
combin antiandrogen chemotherapi may fit nice evolv treatment
paradigm shown aniten compound abl enhanc activ xtandi vitro
preclin model advanc prostat cancer suggest potenti clinic applic compani second-
figur approv metastat castration-resist prostat cancer
approv hormon therapi gonadotropin-releas hormon gnrh key hormon involv
product gonadotropin gnrh also known lutein hormon releas hormon lhrh
necessari product testosteron mean blockad gnrh inhibit testosteron product
reduc testosteron level gnrh antagonist may use combin antiandrogen therapi creat
known combin androgen blockad cab casodex bicalutamid eulexin flutamid antiandrogen
therapi approv hormon sensit prostat cancer bicalutamid lead therapi approv
treatment hormone-sensit prostat cancer given combin zoladex goserelin acet lupron
leuprolid gnrh analogu bicalutamid gener world-wide sale drug million
fiscal year world-wide sale lupron zoladex million million respect
approv treatment metastat crpc progress next line defens usual
chemotherapi commonli prescrib chemotherapi mcrpc docetaxel combin
prednison combin recommend nccn guidelin first chemotherapi
use docetaxel antimitot agent limit cell prolifer induc apoptosi activ divid
cell therapi approv combin prednison treatment patient mcrpc
refractori hormon therapi patient progress docetaxel often treat sanofi nyse
sni jevtana cabazitaxel microtubul inhibitor approv combin prednison patient
mcrpc fail docetaxel phase studi median overal surviv os patient treat
combin jevtana prednison month compar month group receiv
mitoxantron treatment mitoxantron dna intercal agent approv world-wide sale
jevtana million million million million first
month
antiandrogen therapi next class therapi use treat patient mcrpc drug
either inhibit synthesi androgen bind androgen cognat receptor xtandi
enzalutamid co-partn astella oral avail ar inhibitor prevent
ligand bind nuclear transloc subsequ associ dna xtandi approv
patient mcrpc fail chemotherapi approv base pivot phase studi
patient treat drug achiev median os month compar month
placebo xtandi label extend includ chemotherapy-nav patient prevail
phase trial evalu xtandi chemotherapi nave patient radiograph progress free surviv
patient treat xtandi month compar month placebo group extend
analysi mo xtandi group month compar month placebo arm
global sale xtandi billion billion
xtandi main competitor johnson johnson zytiga abirateron acet pro-drug abirateron
inhibitor enzym express prostat cancer
tumor involv androgen synthesi zytiga approv patient either fail
chemotherapi nave treatment phase studi patient zytiga plu prednison arm
achiev overal surviv month compar month receiv prednison plu
zytiga label expand includ pre-chemotherapi patient phase studi
evalu zytiga chemotherapi nave men mcrpc show patient experienc strong
radiograph progress free surviv rpf os compar placebo
world-wide sale zytiga billion billion
de bono et al prednison plu cabazitaxel mitoxantron metastat castrat resist prostat cancer
progress docetaxel treatment random open-label trial lancet
scher et al increas surviv enzalutamid prostat cancer chemotherapi new emgl
de bono et al abirateron increas surviv metastat prostat cancer new engl
immunotherapi valeant nyse vrx proveng sipuleucel-t person cancer vaccin approv
asymptomat minim symptomat mcrpc therapi instruct patient immun system
recogn attack cancer cell way vaccin identifi foreign pathogen proveng approv
support success complet phase studi mo patient treat
proveng month rel month placebo treat patient valeant acquir right
therapi dendreon compani develop proveng file bankruptci due larg part
disappoint commerci launch immunotherapeut factor contribut
unsuccess launch target patient popul cost schedul treatment proveng approv
patient asymptomat minim symptomat howev patient quickli progress
asymptomat mcrpc diseas make tough physician captur patient could benefit
treatment therapi wholesal acquisit cost wac infus repres
full cours therapi ad cost treatment patient requir undergo
rel oner process involv seri apheresi infus requir precis schedul
proveng sale million respect
radiotherapi bayer bayn algeta privat xofigo alpharadin alpha particle-emitt
approv treatment bone metastasi patient fail inelig
treatment docetaxel therapi approv support phase data show
mo patient treat xofigo month compar month placebo arm
hr global sale xofigo million million million
million us sale wac xofigo per month treatment regimen
genet character mcrpc patient offer insight biomark driven clinic studi
prospect identif predict biomark base patient prior treatment histori may key advis
genomic-driven clinic trial comprehens profil androgen receptor ar variant somat genom
alter mcrpc affect individu shed light relev alter clinic set
exampl studi investig genet alter mcrpc suggest affect individu
depend ar signal may result select due ar-direct therapi fact retrospect
analysi liquid biopsi patient show ar splice variant ar-v present half
individu treat abirateron importantli nearli patient resist
moder respons either treatment suggest identif ar-v may use predict
biomark therapi address resist abirateron and/or enzalutamid
molecular profil mcrpc tumor also identifi individu whose tumor harbor ar amplif
concurr alter pathway includ atm import given
alter ar atm associ shorter time protein
associ pathway repres potenti target investig approv drug either singl agent
combin therapi target ar pathway essa aniten compound compani
explor combin regimen aniten compound mtor parp inhibitor preclin studi
abil molecularli character mcrpc biopsi affect individu may help patient stratif
de laer et al comprehens profil androgen receptor liquid biopsi castration-resist
prostat cancer reveal novel intra-ar structur variat splice variant express pattern euro urol
robinson et al integr clinic genom advanc prostat cancer cell
monitor individu receiv therapi order gaug efficaci treatment note
current evalu biomark data phase studi order identifi inform biomark may
use stratifi evalu patient plan phase trial use next-gener aniten compound
epidemiolog estim approxim new case prostat cancer diagnos us
approxim die incid prostat cancer declin
last decad due larg part recommend use prostat specif antigen screen
fact rate prostat cancer diagnosi declin per year patient localized-
advanc diseas surgeri radiat often cur howev roughli develop increas
therapi block androgen product often use treat patient symptomat diseas metastasi
therapi initi effect roughli patient develop resist induc state refer
castrat resist prostat cancer incid metastat form us
expect approxim
market size market prostat cancer treatment larg expect continu grow primari
treatment patient mcrpc chemotherapi therapeut modal inhibit androgen receptor ar
signal therapi includ sanofi aventi jevtana cabazitaxel astella xtandi johnson
johnson zytiga lesser extent valeant proveng sipuleucel-t sale figur therapi shown
figur repres signific portion prostat cancer market sale agent combin
total billion
figur annual sale million current avail mcrpc therapi
astella
hirst et al epidemiolog castrat resist prostat cancer longitudin analysi use uk primari care
scher et al preval prostat cancer clinic state mortal unit state estim use
xtandi zytiga largest player market sale market share xtandi zytiga may increas
futur given therapi receiv expand label includ chemotherapi nave patient earli
valeant enter agreement sell proveng manufactur dendreon pharmaceut privat
follow lacklust launch therapi us eu market
xtandi zytiga pois continu robust sale mcrpc market given physician familiar
therapi howev de novo acquir resist drug occur quit rapidli approxim
patient primari resist therapi experi clinic document mechan
acquir resist includ amplif ar gene acquisit ligand bind domain mutat ar splice
variant bypass pathway independ ar signal factor present opportun new
market entrant enhanc activ either xtandi zytiga induc superior effect singl agent abl
target ar-independ bypass pathway target n-termin domain ar essa aniten compound
may benefit patient develop ar mutat lbd ar gene amplif overexpress ar splice
phase i/ii trial metastat castrat resist prostat cancer
complet phase studi show favor safeti profil modest efficaci men
mcrpc demonstr reduct prostat specif antigen howev studi uncov limit
relat potenc bioavail formul stabil compani sinc refocus
attent screen epi aniten compound higher potenc improv absorpt distribut
metabol excret adm profil
trial design adapt open-label single-arm phase i/ii dose escalation/dos expans studi epi-
patient mcrpc experienc diseas progress treatment xtandi zytiga
studi also includ mcrpc patient refractori docetaxel one round treatment phase
portion studi plan enrol patient receiv oral daili dose rang
mg mg twice daili total mg primari endpoint safeti toler secondari
endpoint includ identifi maximum toler dose recommend phase ii dose addit
rang pharmacokinet paramet exploratori endpoint includ statu circul tumor cell
brief pain inventori
trial result total patient treat discontinu treatment due advers
event gener well toler across dose mg commonli report
mild moder includ diarrhea/nausea fatigu decreas appetit pain extrem
vomit grade includ anemia elev ast neutropenia
gastrointestin report two patient treat mg dose led discontinu
therapi one daili dose cohort one twice daili dose cohort addit one patient
boudadi antonaraki resist novel antiandrogen therapi metastat castrat resist
daili mg cohort experienc transient increas liver enzym deem dose limit toxic
led discontinu therapi time data cutoff twice daili mg dose cohort continu
enrol patient without addit safeti concern
pharmacokinet pk analys serum treat patient evalu day presenc
activ moieti prodrug figur show variou pk measur left panel
right panel depict steady-st plasma concentr time data indic dose-depend
increas cmax auc first hour day dose cohort rang daili mg
right panel trend also observ higher dose cohort left panel compani
state although auc achiev studi similar preclin mous model tempor
pattern exposur distinct support data right panel figur suggest drug
metabol much rapidli human half-lif hour
figur pharmacokinet analysi phase studi
term efficaci studi design measur maximum chang prostat specif antigen
time start multi-dos period depict waterfal plot figur x-axi depict
individu patient y-axi indic chang level decreas level indic reduct
diseas burden suggest benefit patient receiv dose higher equal mg blue bar
whole observ demonstr safeti toler provid proof-of-concept
essa therapeut strategi howev data also highlight limit exampl low
bioavail potenc compound even highest level test suggest formul
use studi optim use knowledg gain clinic studi compani
taken seri step improv upon next gener aniten compound includ increas
vitro potenc next gener compound half maxim inhibitori concentr less
verifi oral activ compound vivo improv adm profil block metabol
figur interim respons treat patient
plan phase trial next-gener aniten compound compani focus select
aniten improv adm profil intend file ind first quarter accept
compani plan initi phase studi second quarter second-gener aniten therapi
metastat patient activ ar signal potenti clinic applic aniten includ
monotherapi mcrpc patient refractori antiandrogen therapi combin approach
second gener antiandrogen treatment modal poli adp-ribos polymeras parp enzym
compani conduct biomark analys circul tumor cell patient enrol complet phase
studi analysi meant identifi put marker may aid patient stratif give indic
treatment efficaci biomark might includ detect ar splice variant and/or prostat
drug develop
xtandi zytiga standard care patient castrat resist prostat cancer howev
signific unmet medic need space given men often progress either therapi molecular
character tumor metastat patient success immunotherapi variou
cancer indic led increas drug develop prostat cancer second gener androgen
receptor ar therapi immunotherapi drug target poli adp-ribos polymeras parp
enzym develop potenti treatment option advanc prostat cancer figur highlight
drug develop diseas
figur prostat cancer drug develop
mammalian target
high-
apalutamid johnson johnson nyse small molecul bind ligand
bind domain lbd ar inhibit nuclear transloc bind dna therapi similar
enzalutamid competit inhibitor ar greater potenc less penetr central
nervou system enzalutamid shown bind gabaa receptor brain could lead risk
seizur johnson johnson acquir apalutamid aragon pharmaceut privat up-front payment
million million conting develop mileston payment
aragon pharmaceut complet phase ii non-random open-label studi evalu apalutamid
treatment men post abirateron studi met primari
endpoint respons week accord prostat cancer work group criteria eighty-eight
percent mcrpc patient treat apalutamid achiev respons week compar favor
patient post-abirateron therapi rate respons week non-metastat
patient median time progress men mcrpc treat abirateron
patient treat apalutamid month respect term safeti
common fatigu diarrhea report seizur
johnson johnson recent submit nda apalutamid men non-metastat nda
support data spartan phase studi expect random men receiv either
apalutamid primari endpoint metastasis-fre surviv notabl secondari endpoint
includ overal surviv os radiograph progress free surviv rpf compani file nda
apalutamid octob expect present data studi genitourinari cancer
symposium februari base standard nda fill pdufa decis apalutamid
occur octob
compani conduct addit phase studi apalutamid titan phase trial evalu
apalutamid plu compar alon patient metastat hormone-sensit prostat
primari endpoint studi os rpf data expect addit compani
conduct atla phase trial evalu apalutamid plu gonadotropin releas hormon gnrh agonist
versu placebo patient local advanc prostat primari endpoint metastat free surviv
secondari endpoint includ os time castrat resist prostat cancer compani expect
complet studi decemb
darolutamid bayer ag bayn darolutamid ar antagonist develop
potenti therapi men progress mcrpc therapi structur differ ar therapi
shown activ mutat ar confer resist antiandrogen therapi
mutat includ darolutamid licens orion
ornbv million term agreement orion bayer
jointli develop drug bayer commerci drug global
orion complet open-label arad phase i/ii studi evalu darolutamid men progress mcrpc
patient random receiv increas dose darolutamid primari endpoint studi
respons week post treatment patient treat mg darolutamid achiev
respons compar patient mg mg cohort term safeti darolutamid well
toler common fatigu decreas appetit
bayer orion current conduct two phase studi arasen arami studi arasen
studi evalu darolutamid plu docetaxel compar docetaxel men metastat
hormon sensit prostat notabl secondari endpoint includ time time next line
therapi pivot arami trial double-blind random placebo control studi evalu daralutamid
versu placebo non-metastat primari endpoint trial metastasi free surviv secondari
endpoint includ os time initi first chemotherapi regimen success therapi potenti
treatment option men metastat diseas sensit hormon therapi therebi cut
xtandi zytiga market share moreov darolutamid activ ar resist set make attract
treatment option xtandi zytiga failur set essa aniten compound may effect
tecentriq atezolizumab roch vtx rog vx tecentriq atezolizumab monoclon antibodi target
program cell ligand roch conduct open-label phase ii studi evalu drug
patient advanc solid tumor includ men advanc prostat primari endpoint
studi percentag individu achiev complet respons partial respons stabl diseas data
studi expect inform on-going random open-label phase studi evalu
tecentriq plu xtandi mcrpc patient fail antiandrogen therapi fail inelig
receiv taxan primari endpoint studi os secondari endpoint includ radiograph
progress free surviv time progress roch tecentriq advanc immun checkpoint
inhibitor develop prostat cancer follow bristol myer squibb opdivo nivolumab merck
keytruda pembrolizumab current phase ii develop treatment men mcrpc
n-termin inhibit could advantag treatment approach ar although
xtandi zytiga standard care patient castrat resist prostat cancer
signific unmet medic need space sinc men often progress either therapi due resist
mechan includ gain-of-funct gof mutat androgen receptor ar ligand bind domain
lbd develop ar splice variant ar-v indiscrimin activ ar glucocorticoid
receptor progesteron receptor activ result need develop new agent essa
second gener aniten address mechan resist essa epi aniten compound may hold advantag
ar antagonist develop darolutamid apalutamid sinc potenti address
ar-gof mutat lbd ar-v ar-amplif ectop activ ar way ar inhibit
agent develop address resist mechan target n-termin domain
ntd attract target sinc critic transcript activ ar moreov target
domain may provid salvag option patient either de novo mutat acquir mutat ar
lbd result xtandi zytiga treatment
aniten may complement evolv prostat cancer treatment landscap treatment landscap
prostat cancer rapidli evolv recent data publish new england journal medicin suggest
ad abirateron androgen deprav therapi explor potenti up-front treatment
option advanc prostat cancer antiandrogen drug regularli use limit androgen activ
howev effect therapi short-liv men ultim progress either treatment impli
greater inhibit androgen may lead improv clinic outcom
initi studi evalu neoadjuv plu abirateron men high-risk local prostat cancer
demonstr reduct intraprostat androgen suggest earli effect androgen suppress may
key limit prostat cancer inde ad abirateron progesteron significantli
increas overal surviv reach vs month hr radiograph progression-fre surviv
month vs month hr men newli diagnos metastat castrat sensit prostat
cancer compar plu dual believ result may posit read-through
drug target ar essa second gener aniten expand patient popul would benefit
treatment
taplin et al intens androgen-depriv therapi abirateron acet leuprolid acet patient
local high-risk prostat cancer result random phase ii neoadjuv studi clin oncolog
fizazi et al abirateron plu prednison metastat castrat sensit prostat cancer new engl jour
second gener antiandrogen becom part up-front treatment regimen patient mcrpc
import point second gener antiandrogen drug vulner variou mechan resist
may requir addit inhibit ar signal end shown addit xtandi
enhanc suppress vitro model prostat cancer highlight possibl therapeut
approach metastat prostat cancer
potenti clinic applic aniten agent molecular profil mcrpc tumor
identifi alter atm antiandrogen therapi import given
alter mani gene associ shorter time progress protein
associ pathway repres valid target investig approv drug either singl agent
combin therapi target ar pathway figur highlight therapi
develop target pathway program repres plausibl combinatori strategi may
explor futur compani also present partnership opportun could yield addit fund
figur list program develop target ar independ pathway
men without
mutat
mutant hr
identifi patient subset new patient popul may differenti clinic trial
design take account novel patient popul use new biomark strategi may import defens
posit first-in-class best-in-class drug especi import indic crowd therapeut
drug class anti-ar therapi end current analyz put biomark circul
tumor cell cell free dna order inform futur studi evalu epi aniten compound strategi may
allow compani valid pharmacodynam put marker exploratori endpoint phase
studi could help genotype/phenotyp enrich go phase iib/iii registr studi
univers british columbia ubc british columbia cancer agenc bcca joint ownership
licens patent patent applic respect compani technolog option
acquir patent applic specifi payment ubc bcca compani composit
matter patent issu us use treatment condit castration-resist
prostat cancer particular patent set expir may remain patent pend patent
applic direct toward altern androgen receptor modul deriv method use
dr parkinson serv director compani sinc june employ full time
presid chief execut offic compani sinc januari respons manag
compani develop object strategi standard perform secur lead team
profession direct deliv requir perform recent dr parkinson serv
ventur partner new enterpris associ board director nea role ventur advisor nea
dr parkinson serv presid ceo nodal biotechnolog compani focus
biolog character signal pathway patient malign enabl effect therapeut
zdevelop clinic decis make dr parkinson previous led oncolog clinic develop activ
novarti biogen idec work nation cancer
institut serv chief investig drug branch act associ
director cancer therapi evalu program ctep
dr parkinson past chairman food drug administr fda biolog advisori committe also
serv fda scienc board recipi fda codi medal serv nation
cancer polici forum institut medicin board director ontario institut cancer research
past co-chair cancer steer committe nih foundat biomark consortium current
serv board director multipl myeloma research foundat serv chairperson
american associ cancer research financ audit committe last year dr parkinson
formerli director facet biotech inc ambit bioscienc public biopharma compani
acquir larg pharma current serv director board cerulean pharma inc inc
held academ posit tuft univers texa md anderson cancer center author
peer- review public
peter virsik serv execut vice presid chief oper offic sinc august mr virsik
year experi corpor develop strategi new product plan allianc manag
financ career mr virsik complet licens financi transact total
billion valu recent serv senior vice presid corpor develop xenoport acquir
arbor pharmaceut lead licens strategi new product plan allianc manag
compani tenur xenoport mr virsik play integr role licens commerci
horiz gabapentin enacarbil prior xenoport mr virsik work
corpor develop involv build gilead hiv franchis acquisit
licens vitekta elvitegravir join gilead mr virsik work
morgan biotechnolog equiti research group consult ernst young mr virsik began
career genentech mr virsik receiv kellogg graduat school manag
northwestern univers ms microbiolog univers michigan ann arbor ba molecular
cellular biolog univers california berkeley
mr wood cfo sinc octob respons manag financi aspect
busi matter relat complianc corpor govern mr wood year experi
manag larg earli stage compani north america
head financ secretari treasur celat pharmaceut inc prior manag director
cubist pharmaceut uk ltd financ director terragen discoveri inc year
biopharmaceut industri mr wood overseen sever transact numer financ rais
million mr wood began career financ explor depart chevron corp receiv
 sc biolog queen univers univers western ontario hold
account design serv govern bodi nation research council canada
execut vice presid research develop
dr cossum serv execut vice presid research develop sinc april
almost year biotechnolog industri experi drug develop scientif manag
role prior join serv presid texa bioallianc ceo proacta evp develop
newbiot vice-president preclin develop director preclin develop
dr cossum began scientif career genentech inc serv member
board director pivot bioscienc inc receiv doctor school pharmaci univers
australia
peer-review
risk invest
consid invest high-risk invest develop stage
compani histori take treatment market current fda approv drug portfolio
compani program limit data date furthermor earli indic efficaci necessarili
translat posit late-stag result clinic trial result signific addit expens compani
may requir addit round dilut financ compani may unabl obtain suffici
capit fund plan develop program regulatori risk associ develop
drug may receiv fda approv candid despit signific time financi invest
regulatori approv market sell drug guarante drug penetr market sale
may meet expect
research analyst denot ac cover report certifi multipl research analyst primarili respons
report research analyst denot ac cover within document individu certifi respect
secur subject compani research analyst cover research view express report accur
reflect person view subject secur subject compani part research
analyst compens directli indirectli relat specif recommend view express research
analyst report
